AlzeCure Pharma: AlzeCure gets New Abstract Accepted on ACD8

STOCKHOLM, SE / ACCESSWIRE / October 18, 2022 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule

Related Keywords

Sweden , Stockholm , San Francisco , California , United States , Swedish , Pontus Forsell , Alzecure Pharma , Nather Madjid , Gunnar Nordvall , Sanja Juric , Cristina Parrado Fern , Johan Sandin , Maria Backlund , Head Of Discovery Research At Alzecure , Head Of Discovery Research At Alzecure Pharma , Clinical Trials , Medicinal Chemistry , Nasdaq First North Premier Growth Market , Nerve Growth Factor , Brain Derived Neurotrophic Factor , Alzecure , Dharma , Jets , Abstract , Accepted , Cd856 , Indicative , Disease , Modifying , Effects , Against , Lzheimer ,